WCBA
GILD icon

Weaver C. Barksdale & Associates’s Gilead Sciences GILD Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Sell
16,939
-54
-0.3% -$7.12K 1.92% 18
2026
Q1 		$2.37M Sell
16,993
-778
-4% -$109K 2.26% 2
2025
Q4 		$2.18M Sell
17,771
-2,032
-10% -$247K 2.29% 5
2025
Q3 		$2.2M Sell
19,803
-1,267
-6% -$144K 2.12% 11
2025
Q2 		$2.34M Sell
21,070
-80
-0.4% -$8.51K 2.24% 5
2025
Q1 		$2.37M Sell
21,150
-2,505
-11% -$258K 2.27% 4
2024
Q4 		$2.19M Sell
23,655
-613
-3% -$55.2K 2.09% 14
2024
Q3 		$2.03M Sell
24,268
-941
-4% -$71.8K 1.83% 20
2024
Q2 		$1.73M Sell
25,209
-337
-1% -$22.5K 1.64% 33
2024
Q1 		$1.87M Sell
25,546
-200
-0.8% -$15.4K 1.72% 27
2023
Q4 		$2.09M Sell
25,746
-6,786
-21% -$528K 2.04% 14
2023
Q3 		$2.44M Buy
32,532
+5,259
+19% +$405K 2.08% 9
2023
Q2 		$2.1M Sell
27,273
-1,680
-6% -$134K 2.08% 7
2023
Q1 		$2.4M Sell
28,953
-1,151
-4% -$95.3K 2.25% 1
2022
Q4 		$2.58M Buy
30,104
+815
+3% +$64.5K 2.28% 1
2022
Q3 		$1.81M Buy
+29,289
New +$1.85M 1.81% 16

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Weaver C. Barksdale & Associates's GILD Position: Q2 2026 in Review

Weaver C. Barksdale & Associates reduced its Gilead Sciences (GILD) stake by 0.32% in Q2 2026, selling an estimated $7.12K and leaving 16,939 shares worth $2.14M. The position accounts for 1.92% of the portfolio, ranked #18.

Weaver C. Barksdale & Associates first reported a position in GILD in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.58M in Q4 2022. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Weaver C. Barksdale & Associates held 16,939 shares of Gilead Sciences worth $2.14M as of Q2 2026.
  • Weaver C. Barksdale & Associates sold 54 Gilead Sciences shares in Q2 2026, an estimated $7.12K.
  • Gilead Sciences made up 1.92% of Weaver C. Barksdale & Associates's portfolio in Q2 2026, its #18 holding.
  • Weaver C. Barksdale & Associates first reported a position in Gilead Sciences in Q3 2022 and has held it in 16 quarters since.
  • Weaver C. Barksdale & Associates's Gilead Sciences position peaked at $2.58M in Q4 2022.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.